• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Emerging Gold Standard?


San Francisco - More than two decades after collagen launched a revolution in filling facial wrinkles, the FDA is expected to approve the soft filler hyaluronic acid (Restylane, Q-Med) within the next few months. The approval will be partly based on a phase III study that showed it provides longer-lasting correction of nasolabial folds than collagen.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.